Selective Cannabinoid Receptor-1 Agonists Regulate Mast Cell Activation in an Oxazolone-Induced Atopic Dermatitis Model
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background: Many inflammatory mediators, including various cytokines (e.g. interleukins and tumor necrosis factor [TNF]), inflammatory proteases, and histamine are released following mast cell activation. However, the endogenous modulators for mast cell activation and the underlying mechanism have yet to be elucidated. Endogenous cannabinoids such as palmitoylethanolamide (PEA) and N-arachidonoylethanolamine (anandamide or AEA), were found in peripheral tissues and have been proposed to possess autacoid activity, implying that cannabinoids may downregulate mast cell activation and local inflammation. Objective: In order to investigate the effect of cannabinoid receptor-1 (CB1R) agonists on mast cell activation, AEA-derived compounds were newly synthesized and evaluated for their effect on mast cell activation. Methods: The effects of selected compounds on FcRI-induced histamine and β-hexosaminidase release were evaluated in a rat basophilic leukemia cell line (RBL-2H3). To further investigate the inhibitory effects of CB1R agonist in vivo, an oxazolone-induced atopic dermatitis mouse model was exploited. Results: We found that CB1R inhibited the release of inflammatory mediators without causing cytotoxicity in RBL-2H3 cells and that CB1R agonists markedly and dose-dependently suppressed mast cell proliferation indicating that CB1R plays an important role in modulating antigen-dependent immunoglobulin E (IgE)-mediated mast cell activation. We also found that topical application of CB1R agonists suppressed the recruitment of mast cells into the skin and reduced the level of blood histamine. Conclusion: Our results indicate that CB1R agonists downregulate mast cell activation and may be used for relieving inflammatory symptoms mediated by mast cell activation, such as atopic dermatitis, psoriasis, and contact dermatitis.
Abstract
Background: Many inflammatory mediators, including various cytokines (e.g. interleukins and tumor necrosis factor [TNF]), inflammatory proteases, and histamine are released following mast cell activation. However, the endogenous modulators for mast cell activation and the underlying mechanism have yet to be elucidated. Endogenous cannabinoids such as palmitoylethanolamide (PEA) and N-arachidonoylethanolamine (anandamide or AEA), were found in peripheral tissues and have been proposed to possess autacoid activity, implying that cannabinoids may downregulate mast cell activation and local inflammation. Objective: In order to investigate the effect of cannabinoid receptor-1 (CB1R) agonists on mast cell activation, AEA-derived compounds were newly synthesized and evaluated for their effect on mast cell activation. Methods: The effects of selected compounds on FcRI-induced histamine and β-hexosaminidase release were evaluated in a rat basophilic leukemia cell line (RBL-2H3). To further investigate the inhibitory effects of CB1R agonist in vivo, an oxazolone-induced atopic dermatitis mouse model was exploited. Results: We found that CB1R inhibited the release of inflammatory mediators without causing cytotoxicity in RBL-2H3 cells and that CB1R agonists markedly and dose-dependently suppressed mast cell proliferation indicating that CB1R plays an important role in modulating antigen-dependent immunoglobulin E (IgE)-mediated mast cell activation. We also found that topical application of CB1R agonists suppressed the recruitment of mast cells into the skin and reduced the level of blood histamine. Conclusion: Our results indicate that CB1R agonists downregulate mast cell activation and may be used for relieving inflammatory symptoms mediated by mast cell activation, such as atopic dermatitis, psoriasis, and contact dermatitis.
참고문헌 (22)
- Gaoni Y., "Isolation, structure, and partial synthesis of an active constituent of hashish", J Am Chem Soc, 86, pp.1646~1647 (1964)
- Pertwee RG, "Pharmacology of cannabinoid CB1 and CB2 receptors", Pharmacol Ther, 74, pp.129~180 (1997)
- Howlett AC., "XXVII. Classification of cannabinoid receptors", Pharmacol Rev, 54, pp.161~202 (2002)
- Matsuda LA., "Structure of a cannabinoid receptor and functional expression of the cloned cDNA", Nature, 346, pp.561~564 (1990)
- Munro S., "Molecular characterization of a peripheral receptor for cannabinoids", Nature, 365, pp.61~65 (1993)
- Childers SR., "Role of cyclic AMP in the actions of cannabinoid receptors", Biochem Pharmacol, 52, pp.819~827 (1996)
- Ständer S., "Distribution of cannabinoid receptor 1(CB1)and 2(CB2)on sensory nerve fibers and adnexal structures in human skin", J Dermatol Sci, 38, pp.177~188 (2005)
- Buckley NE, "The peripheral cannabinoid receptor knockout mice : an update", Br J Pharmacol, 153, pp.309~318 (2008)
- Klein TW., "The cannabinoid system and immune modulation", J Leukoc Biol, 74, pp.486~496 (2003)
- Derocq JM., "Cannabinoids enhance human B-cell growth at low nanomolar concentrations", FEBS Lett, 369, pp.177~182 (1995)
- Stone KD., "IgE, mast cells, basophils, and eosinophils", J Allergy Clin Immunol, 125(2 Suppl 2), pp.S73~S80 (2010)
- Aloe L., "A proposed autacoid mechanism controlling mastocyte behaviour", Agents Actions, 39, pp.C145~C147 (1993)
- Facci L., "Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide", Proc Natl Acad Sci U S A, 92, pp.3376~3380 (1995)
- Sun N., "Use of a rat basophil leukemia(RBL)cell-based immunological assay for allergen identification, clinical diagnosis of allergy, and identification of anti-allergy agents for use in immunotherapy", J Immunotoxicol, 12, pp.199~205 (2015)
- Maeyama K., "Quantitative relationships between aggregation of IgE receptors, generation of intracellular signals, and histamine secretion in rat basophilic leukemia (2H3) cells. Enhanced responses with heavy water", J Biol Chem, 261, pp.2583~2592 (1986)
- Samson MT., "Differential roles of CB1 and CB2 cannabinoid receptors in mast cells", J Immunol, 170, pp.4953~4962 (2003)
- Sugawara K., "Endocannabinoids limit excessive mast cell maturation and activation in human skin", J Allergy Clin Immunol, 129, pp.726.e8~738.e8 (2012)
- Hae-Jin Lee, "The Effect of Adipose-Derived Stem Cell-Cultured Media on Oxazolone Treated Atopic Dermatitis-Like Murine Model", Annals of Dermatology, 24(2), pp.181~188 (2012), 대한피부과학회[DOI]
- Jutel M., "Histamine, histamine receptors and their role in immune pathology", Clin Exp Allergy, 39, pp.1786~1800 (2009)
- Lambert DM., "Analogues and homologues of N-palmitoylethanolamide, a putative endogenous CB(2)cannabinoid, as potential ligands for the cannabinoid receptors", Biochim Biophys Acta, 1440, pp.266~274 (1999)
- Bueb JL., "Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro", Biochim Biophys Acta, 1538, pp.252~259 (2001)
- Oka S., "Involvement of the cannabinoid CB2 receptor and its endogenous ligand 2-arachidonoylglycerol in oxazolone-induced contact dermatitis in mice", J Immunol, 177, pp.8796~8805 (2006)